On May 1, 2023, the U.S. Food and Drug Administration announced it had conditionally approved Varenzin-CA1 (molidustat oral suspension) a new medication for cats! This is the first drug for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.

The slow demise of a beloved cat while battling chronic kidney disease is difficult to witness with no FDA approved medication to address anemia. This new medication has been shown to stimulate cats to eat and is easily administered at home to by owners orally.

Read more detailed information about Varenzin-CA1 from the makers of this new drug.

Editor’s Note: The makers of Varenzin-CA1 had no input in the story and TICA received no funding.